Exagen Diagnostics reports plans to price initial public sale of stock

Leerink Partners and Baird are bookrunners; William Blair assists

By Devika Patel

Knoxville, Tenn., Sept. 19 – Exagen Diagnostics, Inc. will conduct an initial public offering of its common stock with a 30-day greenshoe option, according to a Form S-1 filed Friday with the Securities and Exchange Commission.

Leerink Partners and Baird are the joint bookrunning managers. William Blair is the co-manager.

Proceeds will be used for marketing, research and development, capital expenditures, working capital and other general corporate purposes.

The commercial-stage diagnostics company is based in Vista, Calif. It intends to list its common stock on the Nasdaq under the symbol “EXDX.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.